General Archive
-
News releasesLifeArc and the Gates Foundation launches groundbreaking new projects to lower the cost of monoclonal antibody production
We have partnered with the Gates Foundation to fund seven new projects aimed at reducing the costs of manufacturing monoclonal…
-
News releasesPACE announces £6 million funding for antibacterial treatment innovations to fill critical gap in R&D pipeline
PACE (Pathways to Antimicrobial Clinical Efficacy) launches its third funding round today, supporting innovative projects that tackle resistant bacterial infections…
-
News releasesC-Further announces major partnership with GOSH Charity to drive innovation in childhood cancer treatment
Great Ormond Street Hospital Charity (GOSH Charity), the UK’s largest dedicated charitable funder of child health research, has joined us…
-
News releasesInnovative home monitoring service aims to improve care for patients with dementia
Imperial College Healthcare NHS Trust has launched a new NHS service for people living with dementia, offering remote, at-home monitoring…
-
News releasesLifeArc launches first study of Our Future Health data using in-house data science capabilities
Our Future Health holds rich, in-depth data on its consented participants. For future research and the development of new tests…
-
News releasesLifeArc joins transatlantic collaboration to develop a treatment for Crimean-Congo Hemorrhagic Fever
A new transatlantic collaboration between the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and LifeArc will look to…
-
Articles, News releasesLifeArc joins the REMEDi4ALL Consortium, a pioneering global platform shaping the future of drug repurposing
LifeArc and the EU-funded project, REMEDi4ALL, have announced a collaboration agreement to strengthen the partnership’s potential to transform and accelerate…
-
News releases£1 million partnership aims to develop new treatments for congenital muscular dystrophy
Researchers from University College London have jointly received a £1 million grant from LifeArc and Muscular Dystrophy UK, to develop…
-
News releasesTribune Therapeutics raises EUR 37 million for next-generation anti-fibrotic therapies
Tribune Therapeutics AB, a biotechnology company dedicated to treating the root causes of fibrotic diseases, today announced it has raised…
-
News releasesHillstar Bio closes $67 million Series A financing round
Hillstar Bio, a leading biotechnology company focused on developing next-generation precision immunology therapies for autoimmune diseases, today announced the successful…
-
News releasesLifeArc invests in Maxion Therapeutics Series A
Maxion Therapeutics (“Maxion”), a biotechnology company developing antibody-based KnotBody® drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases,…
-
News releasesLifeArc and Neuropeutics Inc join forces to advance a new treatment for MND/ALS
LifeArc has announced a collaboration with Neuropeutics Inc to develop a new small molecule for the treatment of motor neuron…